Additionally, ERK1/2 pathway and NF-κB pathway have been reported to be activated by TBL1XR1 in GC and NPC, suggesting that TBL1XR1 played an important role in cancer progression and drug resistance and may act as a new therapeutic target for those cancers [12, 14]. Here, TBL1XR1 is linked to nasopharyngeal carcinoma.